(Q54184065)

English

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.

scientific article published in January 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

author name string

S K Williamson

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

M K Wolf

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

M A Eisenberger

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

M O'Rourke

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

W Brannon

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

E D Crawford

6

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

publication date

1 January 1995

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

13

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

167-170

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

https://scigraph.springernature.com/pub.10.1007/bf00872867

0 references

The chemotherapy of prostatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8617581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of didemnin B in the human tumor stem cell assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/8617581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8617581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate

1 reference

https://pubmed.ncbi.nlm.nih.gov/8617581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/8617581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00872867

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8617581

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54184065&oldid=1388881526"